Table 2.

Risk of outcome events between the ACE inhibitor versus the ARB groups or between the ACE inhibitor versus Thiazide groups

Outcomes	ACE inhibitor		ARB		Calibrated HR [95% CI]	ACE inhibitor		Thiazide		Calibrated HR [95% CI]
	N	IRa	N	IR§		N	IR§	N	IRa
South Korea
Total population	21 410	0.44	577 637	0.22	1.47 [0.70–3.10]	9 852	0.57	70 491	0.53	0.88 [0.22–3.46]
≥45 years	15 405	0.57	431 745	0.27	1.36 [0.64–2.88]	7 639	0.66	55 106	0.57	1.98 [0.42–9.21]
United States
Total population	2 130 393	0.43	2 151 531	0.37	1.14 [0.98–1.32]	1 777 108	0.54	1 864 047	0.65	0.91 [0.78–1.07]
≥45 years	1 792 503	0.41	1 813 979	0.35	1.22 [1.04–1.43]b	1 316 424	0.47	1 359 260	0.54	0.89 [0.74–1.07]

^aIncidence rates were calculated as case per 1 000 person-years; ^bstatistically significant

ACE, Angiotensin Converting Enzyme; ARB, Angiotensin II Receptor Blockers, IR: Incidence rates; HR: hazard ratio; CI: 95% confidence interval